'

Subscribe to Hematology News

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tisotumab vedotin shows promise in recurrent, metastatic cervical cancer

Publish date:: March 26, 2019

Key clinical point: Tisotumab vedotin shows encouraging activity and tolerability in heavily pretreated recurrent or metastatic cervical cancer.

Major finding: ORR in 55 cervical cancer patients was 35%, confirmed ORR was 22%.

Study details: A phase 1/2a expansion study of 55 patients

Disclosures: The innovaTV 201 trial is sponsored by Genmab A/S. Dr. Hong reported having no disclosures.

Citation:

Hong DS et al. SGO 2019, Abstract 19.

This Week's Must Reads

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,

Neoadjuvant immunotherapy combo produces high response rate in melanoma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,

Pigment traits, sun sensitivity associated with risk of non-Hodgkin lymphomas and chronic lymphocytic leukemia,

Must Reads in Gynecologic Cancer

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Half of women treated for gynecologic cancers miss or skip doses of oral drugs,

New cancer drugs may have saved more than 1.2 million Americans,

‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients,

Atezolizumab strikes out in ovarian cancer,